KYMR Quote, Financials, Valuation and Earnings

Exelixis has a net margin of -296.75% compared to Kymera Therapeutics's net margin of 28.74%. Kymera Therapeutics's return on equity of -30.8% beat Exelixis's return on equity of 29.53%.

Kymera Therapeutics has a consensus price target of $60.53, signalling upside risk potential of 34.77%. On the other hand Exelixis has an analysts' consensus of $45.89 which suggests that it could grow by 4.16%. Given that Kymera Therapeutics has higher upside potential than Exelixis, analysts believe Kymera Therapeutics is more attractive than Exelixis.

Kymera Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Exelixis has a beta of 0.283, suggesting its less volatile than the S&P 500 by 71.722%.

Kymera Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kymera Therapeutics pays -- of its earnings as a dividend. Exelixis pays out -- of its earnings as a dividend.

Kymera Therapeutics quarterly revenues are $22.1M, which are smaller than Exelixis quarterly revenues of $555.4M. Kymera Therapeutics's net income of -$65.6M is lower than Exelixis's net income of $159.6M. Notably, Kymera Therapeutics's price-to-earnings ratio is -- while Exelixis's PE ratio is 20.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kymera Therapeutics is 59.02x versus 5.59x for Exelixis. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of -296.75% compared to Kymera Therapeutics's net margin of 19.72%. Kymera Therapeutics's return on equity of -30.8% beat Gilead Sciences's return on equity of 32.29%.

Kymera Therapeutics has a consensus price target of $60.53, signalling upside risk potential of 34.77%. On the other hand Gilead Sciences has an analysts' consensus of $116.85 which suggests that it could grow by 7.14%. Given that Kymera Therapeutics has higher upside potential than Gilead Sciences, analysts believe Kymera Therapeutics is more attractive than Gilead Sciences.

Kymera Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.290, suggesting its less volatile than the S&P 500 by 71.014%.

Kymera Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.86% to investors and pays a quarterly dividend of $0.79 per share. Kymera Therapeutics pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Kymera Therapeutics quarterly revenues are $22.1M, which are smaller than Gilead Sciences quarterly revenues of $6.7B. Kymera Therapeutics's net income of -$65.6M is lower than Gilead Sciences's net income of $1.3B. Notably, Kymera Therapeutics's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 22.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kymera Therapeutics is 59.02x versus 4.79x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -296.75% compared to Kymera Therapeutics's net margin of 26.7%. Kymera Therapeutics's return on equity of -30.8% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Kymera Therapeutics has a consensus price target of $60.53, signalling upside risk potential of 34.77%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $728.55 which suggests that it could grow by 32.96%. Given that Kymera Therapeutics has higher upside potential than Regeneron Pharmaceuticals, analysts believe Kymera Therapeutics is more attractive than Regeneron Pharmaceuticals.

Kymera Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.458%.

Kymera Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.32% to investors and pays a quarterly dividend of $0.88 per share. Kymera Therapeutics pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Kymera Therapeutics quarterly revenues are $22.1M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Kymera Therapeutics's net income of -$65.6M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Kymera Therapeutics's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 13.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kymera Therapeutics is 59.02x versus 4.44x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sanofi SA has a net margin of -296.75% compared to Kymera Therapeutics's net margin of 17.65%. Kymera Therapeutics's return on equity of -30.8% beat Sanofi SA's return on equity of 8.47%.

Kymera Therapeutics has a consensus price target of $60.53, signalling upside risk potential of 34.77%. On the other hand Sanofi SA has an analysts' consensus of $62.57 which suggests that it could grow by 30.04%. Given that Kymera Therapeutics has higher upside potential than Sanofi SA, analysts believe Kymera Therapeutics is more attractive than Sanofi SA.

Kymera Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sanofi SA has a beta of 0.489, suggesting its less volatile than the S&P 500 by 51.088%.

Kymera Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sanofi SA offers a yield of 4.56% to investors and pays a quarterly dividend of $2.20 per share. Kymera Therapeutics pays -- of its earnings as a dividend. Sanofi SA pays out 84.6% of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Kymera Therapeutics quarterly revenues are $22.1M, which are smaller than Sanofi SA quarterly revenues of $11.2B. Kymera Therapeutics's net income of -$65.6M is lower than Sanofi SA's net income of $2B. Notably, Kymera Therapeutics's price-to-earnings ratio is -- while Sanofi SA's PE ratio is 17.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kymera Therapeutics is 59.02x versus 2.47x for Sanofi SA. Usually stocks with elevated PS ratios are considered overvalued.